Navigation Links
Biosimilars of Rituxan, MabThera, Herceptin and Erbitux will Erode $8.2 Billion in U.S. and European Sales in 2018
Date:9/15/2009

WALTHAM, Mass., Sept. 15 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018. Biosimilars of these three branded agents are forecasted to erode $8.2 billion in U.S. and European sales in 2018 but they are expected to capture only $4.6 billion in sales due to their lower prices.

"Biosimilars of the five brands covered in this report (Rituxan/MabThera, Erbitux, Herceptin, Amgen's Neupogen and Neulasta) will erode $34.3 billion in brand sales during our 2008-2018 forecast period across the U.S. and Europe and save health care systems $17.3 billion in the process," stated Michael Malecki, Ph.D., analyst and product manager at Decision Resources.

The new special report entitled Biosimilars: G-CSFs and Monoclonal Antibodies in Oncology also finds that oncologists are expected to demand clinical data for biosimilars demonstrating equivalence in multiple subpopulations. That is, although a biosimilar may be labeled for use in multiple subpopulations, oncologists will not feel comfortable prescribing a biosimilar without clinical validation.

Over time, oncologists are expected to become more comfortable using biosimilars in subpopulations and/or indications for which the reference product is approved but not clinically validated. In order to slow the growth of physician comfort in this regard, makers of branded biologics should emphasize the proven efficacy records of their agents and the importance of using a fully validated therapy for patients with life-threatening disease.

"Although surveyed oncol
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GPhA Statement on Introduction of H.R. 1548, The Pathway for Biosimilars Act
2. Decision Resources White Paper Discusses Increasing Reality of Biosimilars and their Impact on Biologics Market
3. Broad Stakeholder Coalition Concludes that the Pathway for Biosimilars Act Fails to Ensure Timely Access to Safe, Affordable Biogeneric Medicines for Patients
4. Routine Testing Would Improve Herceptin Use in Breast Cancer
5. Mathematical modeling predicts response to Herceptin
6. If Herceptin is Approved in Combination With Other Emerging Therapies it Will be in a Position to Retain Patient Share From Tykerb/Tyverb for the Treatment of HER2-Positive Breast Cancer
7. Xeloda(R), Taxotere(R) and Herceptin(R) Combination Study Suggests Clinical Benefit in Invasive Breast Cancer with Shortened Treatment Cycle
8. Herceptin helps women with multiple chromosomes containing HER2 gene, study finds
9. Erbitux May Help Some With Colorectal Cancer
10. Use of Avastin and Erbitux in the Adjuvant Setting and Launches of Emerging Agents Will Drive the Colorectal Cancer Drug Market to $7.8 Billion in 2017
11. Erbitux Works Well for Two-Thirds of Colon Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... Highly regarded audiologist , Dr. Mary Ann Larkin has ... four reports are titled:, , Revealing the Truth ... , The Top 5 Things You Should Know Before ... in Children , Dr. Mary Anne Larkin choose to ... confusion and misinformation about each them. The reports are available ...
(Date:8/29/2014)... La Mirada, CA (PRWEB) August 29, 2014 ... multidisciplinary healthcare organizations, acquired a new medical center from LAXMed. ... LAX airport and less than 2 miles west of the ... Healthpointe center within Southern California. The new LAX center is ... CA 90045. , The new Healthpointe LAX ...
(Date:8/29/2014)... August 29, 2014 The family of ... a series of dialysis treatments has filed a GranuFlo ... was the result of Fresenius Medical Care’s GranuFlo and ... lawsuit, which was file d in Alameda County Superior ... of the products resulted in metabolic alkalosis, a ...
(Date:8/29/2014)... IL (PRWEB) August 29, 2014 ... “The Safety Chick” who profiled a handful of ... Earphones from Etymotic Research. This year, many schools ... and Etymotic, an innovator of hearing wellness solutions, ... Their ETY•Kids Safe-Listening Earphones, offered in yellow, pink ...
(Date:8/29/2014)... Steven Reinberg ... News) -- The vast majority of American babies are ... serious illnesses, federal health officials said Thursday. More ... that prevent measles, mumps, and rubella (MMR); polio; hepatitis ... for Disease Control and Prevention. "Nationally, vaccination among ...
Breaking Medicine News(10 mins):Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 2Health News:Charleston SC Audiologist, Dr. Mary Ann Larkin Authors Four New Special Reports on Important Hearing Healthcare Topics 3Health News:Healthpointe Obtains a New Medical Clinic in the LAX Area 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuit News: Family Alleges Woman’s Death Following Dialysis Was Caused by GranuFlo and NaturaLyte, Bernstein Liebhard LLP Reports 4Health News:The Today Show Features ETY•Kids® Safe-Listening Earphones by Etymotic 2Health News:Most U.S. Babies Get Their Vaccines: CDC 2Health News:Most U.S. Babies Get Their Vaccines: CDC 3
... Meeting of the European Society of Cardiology Council on ... with the Irish Nurses Cardiovascular Association (INCA), is being ... 24-25 April. , The meeting - considered by ... and allied health professionals - will show case the ...
... American Heart Association has partnered with Wiley-Blackwell to ... American Heart Association Clinical Series, designed to help ... patient care. , Each hardcover volume focuses ... on their areas of individual expertise under the ...
... YARDLEY, Pa., April 8 Core Essence Orthopaedics, ... tissue and skeletal repair of the extremities, today ... from the Food and Drug Administration (FDA) for ... in minimally invasive, arthroscopic surgery. SECURUS provides increased ...
... Educational Software (AES), a leading provider of software for ... to announce the addition of Susan DuRant to the ... is the parent of a child with autism and ... be a great asset to our company and help ...
... sales of OTC drugs grew by 2.4% from $17.8 ... to the latest research in Nonprescription Drugs USA ... and research firm Kline & Company.Private-label OTC medicines were ... antacids and allergy medicines posted the highest growth last ...
... A Florida judge has ruled that a state ... bona fide professional organizations is unconstitutional and violates the ... The American Academy of Implant Dentistry (AAID) said today ... qualifications and experience of dentists who perform implant procedures ...
Cached Medicine News:Health News:Telemonitoring changes the working practice of cardiac nurses 2Health News:Telemonitoring changes the working practice of cardiac nurses 3Health News:Telemonitoring changes the working practice of cardiac nurses 4Health News:Telemonitoring changes the working practice of cardiac nurses 5Health News:Telemonitoring changes the working practice of cardiac nurses 6Health News:Wiley-Blackwell and the American Heart Association present new book series 2Health News:Core Essence Receives FDA Approval for SECURUS(TM), an Innovative Knotless Suture Anchor System 2Health News:Core Essence Receives FDA Approval for SECURUS(TM), an Innovative Knotless Suture Anchor System 3Health News:Autism Software Developer Announces Hiring of Susan DuRant as Director of Education 2Health News:Private-label OTC Drugs Post Solid Gains in 2008, According to Kline 2Health News:Private-label OTC Drugs Post Solid Gains in 2008, According to Kline 3Health News:AAID Hails Florida Court Verdict Allowing Advertising of Bona Fide Dental Credentials 2
(Date:8/29/2014)... Aug. 29, 2014  Abaxis, Inc. (NasdaqGS: ... instrumentation and consumables to the medical, research and veterinary ... and Chief Executive Officer, will present at the CL ... on Tuesday, September 9, 2014 at 12:30 p.m. ET. ... Place Hotel in New York City ...
(Date:8/29/2014)... Research and Markets  has announced the addition of ... 2014-2018" report to their offering. ... connect, support, or surround bones. There are several types ... fascia, and other fibrous tissues. Repetitive use, accidents, injuries, ... in wear and tear in these tissues. Orthopedic soft ...
(Date:8/28/2014)... 28, 2014  Rigrodsky & Long, P.A.: , ... (NYSE: LCI )? , Did you purchase your ... July 16, 2014, inclusive? , Did you lose money ... you want to discuss your rights? ... Attorney, Timothy J. MacFall , announces that a complaint has ...
Breaking Medicine Technology:Abaxis, Inc. to Present at CL King's 12th Annual Best Ideas Conference 2014 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 2Global Orthopedic Soft Tissue Repair Devices Market 2014-2018: Key Vendors are ArthroCare, Biomet, DePuy Synthes and Smith & Nephew 3Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 2Rigrodsky & Long, P.A. Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against Lannett Company, Inc. 3
Sprint Quattro Secure™ is a Steroid-Eluting, True Bipolar, Active Fixation ICD Lead....
TVL defibrillation leads have a patented coiled-coil design for faster, easier insertion and more precise intracardiac placement. Designed with an integrated bipolar design, the lead enables high-vol...
The TVL-ADX lead is a thin, high-performing defibrillation lead that offers a true bipolar configuration designed for smarter sensing and low defibrillation threshold for greater patient safety margi...
... SPL defibrillator lead features a ... the flexibility and maneuverability of ... the physician who prefers a ... the SPL lead also promotes ...
Medicine Products: